{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:48:35Z","timestamp":1794552515777,"version":"4.9.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for patients with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001 study. Primary end points were adverse events (AEs), dose-limiting toxicities, and objective response rate (ORR) per independent review committee. Key secondary end points were complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). After 2-year follow-up, patients could enroll in a separate study assessing long-term (\u226415 years) safety and OS. Liso-cel\u2013treated patients (N\u00a0= 270) had a median age of 63 years (range, 18-86 years) and a median of 3 prior lines (range, 1-8) of systemic therapy, and 181 of them (67%) had chemotherapy-refractory LBCL. Median follow-up was 19.9 months. In efficacy-evaluable patients (N\u00a0= 257), the ORR was 73% and CR rate was 53%. The median (95% confidence interval) DOR, PFS, and OS were 23.1 (8.6 to not reached), 6.8 (3.3-12.7), and 27.3 months (16.2-45.6), respectively. Estimated 2-year DOR, PFS, and OS rates were\u00a049.5%, 40.6%, and 50.5%, respectively. In the 90-day treatment-emergent period (N\u00a0= 270), grade 3 to 4 cytokine release syndrome and neurological events occurred in 2% and 10% of patients, respectively. The most common grade \u22653 AEs in treatment-emergent and posttreatment-emergent periods, respectively, were neutropenia (60% and 7%) and anemia (37% and 6%). Liso-cel demonstrated durable remissions and a manageable safety profile with no new safety signals during the 2-year follow-up in patients with R\/R LBCL. These trials were registered at www.ClinicalTrials.gov as #NCT02631044 and #NCT03435796.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020854","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T16:21:14Z","timestamp":1698423674000},"page":"404-416","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":196,"title":["Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"1Lymphoma Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"2Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-7064","authenticated-orcid":false,"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"3Department of Hematology\/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"4Hematology\/Oncology Division, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Lymphoma\/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"6Department of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkhtsetseg","family":"Purev","sequence":"additional","affiliation":[{"name":"7University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"8Clinical Research Division Medicine and Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Andreadis","sequence":"additional","affiliation":[{"name":"9University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sehgal","sequence":"additional","affiliation":[{"name":"10University of Pittsburgh Medical Center: Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[{"name":"11Transplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"12Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dehner","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonhee","family":"Kim","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"14Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kostic","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024020116213851700_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024020116213851700_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","article-title":"Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"55","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2024020116213851700_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024020116213851700_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.14922","article-title":"Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era","volume":"183","author":"Thanarajasingam","year":"2018","journal-title":"Br J Haematol"},{"key":"2024020116213851700_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"issue":"24","key":"2024020116213851700_bib6","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2024020116213851700_bib7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024020116213851700_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024020116213851700_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024020116213851700_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"2024020116213851700_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024020116213851700_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"355","key":"2024020116213851700_bib13","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"21","key":"2024020116213851700_bib14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024020116213851700_bib15","first-page":"4471","article-title":"JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL","volume":"130","author":"Ramsborg","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024020116213851700_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PPO.0000000000000036","article-title":"Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition","volume":"20","author":"Riddell","year":"2014","journal-title":"Cancer J"},{"issue":"20","key":"2024020116213851700_bib17","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2024020116213851700_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/jnci\/djy196","article-title":"Seamless designs: current practice and considerations for early-phase drug development in oncology","volume":"111","author":"Hobbs","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"2024020116213851700_bib19","unstructured":"US Food and Drug Administration\n          . Expansion cohorts: use in first-in-human clinical trials to expedite development of oncology drugs and biologics - guidance for industry. Accessed 9 November 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics."},{"issue":"27","key":"2024020116213851700_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024020116213851700_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2024020116213851700_bib22","unstructured":"US Department of Health and Human Services\n          . National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Accessed 11 October 2022. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"issue":"1","key":"2024020116213851700_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In\u00a0vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2024020116213851700_bib24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","article-title":"Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma","volume":"60","author":"Ogasawara","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"10343","key":"2024020116213851700_bib25","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"for the TRANSFORM Investigators. Lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell therapy, versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the randomised, open-label TRANSFORM phase 3 study","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"2024020116213851700_bib26","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation","volume":"95","author":"Pedersen-Bjergaard","year":"2000","journal-title":"Blood"},{"key":"2024020116213851700_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma\u00a0cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"2024020116213851700_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024020116213851700_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","article-title":"Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies","volume":"10","author":"Elstrom","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2024020116213851700_bib30","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024020116213851700_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of car T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"2024020116213851700_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024020116213851700_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024020116213851700_bib34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-term (\u2265 4 year and \u2265 5 year) overall survival (OS) by 12-and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024020116213851700_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024020116213851700_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024020116213851700_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024020116213851700_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","article-title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","volume":"11","author":"Cartron","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"2024020116213851700_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10428194.2022.2160200","article-title":"Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed\/refractory large B-cell lymphoma","volume":"64","author":"Van Le","year":"2023","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/404\/2210929\/blood_bld-2023-020854-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/404\/2210929\/blood_bld-2023-020854-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:23:02Z","timestamp":1706786582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/5\/404\/498484\/Two-year-follow-up-of-lisocabtagene-maraleucel-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020854","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}